Abstract
Biomarkers hold promise for identifying high-risk individuals who may go on to develop IBD as well as prognosticate disease behavior. Stool markers have not been readily accepted but may be more sensitive and specific than our serum biomarkers for evaluating disease activity. Ultimately, genomic and proteomic approaches will be used to identify novel biomarkers in IBD.
| Original language | English |
|---|---|
| Pages (from-to) | S187-189 |
| Journal | Inflammatory Bowel Diseases |
| Volume | 14 Suppl 2 |
| State | Published - Oct 2008 |